On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to ‘go very big’ on BD

Nicole DeFeudis

Editor

Pfizer CEO Albert Bourla uncorked some record-breaking Q2 numbers on Thursday, including the company’s highest-ever quarterly sales thanks to Comirnaty and Paxlovid, all while raising …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to ‘go very big’ on BD

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

On heels of record-break­ing Q2, Pfiz­er CEO Al­bert Bourla out­lines plans to ‘go very big’ on BD

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to ‘go very big’ on BD